Sticking to hottest trends in biopharma, Oncologie gathers $80M for next leg of trans-Pacific clinical journey
When Oncologie launched last year, it highlighted its trendy model of operating between Boston and Shanghai amid a wave of Chinese capital eager to back experienced US execs in developing Western cancer drugs for the Asian market. For its Series B, it’s allying itself with another buzzy concept in the industry — choosing the right patients by biomarkers.
Nan Fung Life Sciences and Pivotal BioVentures China came back to lead the $80 million round designed to speed up clinical development as well as ramping up partnering and acquisition of new assets, according to CEO Laura Benjamin.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.